Medisys buys Lukens Medical for $12.4 million:
This article was originally published in Clinica
Medisys, the UK-based point-of-care device company, has agreed to pay $12.4 million for Lukens Medical, a wound closure and suture company. Nasdaq-quoted Lukens was founded in 1906 and has recently diversified into sharps disposal and lancets used in diabetes testing. Medisys regards the purchase as a cost-effective way to penetrate the US market. Medisys' diabetes subsidiary Hypoguard has been hit by increased competition and delays in new product launches.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.